5.06
+0.0101(+0.20%)
Currency In USD
| Previous Close | 5.05 |
| Open | 5.06 |
| Day High | 5.09 |
| Day Low | 5 |
| 52-Week High | 5.21 |
| 52-Week Low | 2.3 |
| Volume | 31,449 |
| Average Volume | 129,975 |
| Market Cap | 431.4M |
| PE | -9.73 |
| EPS | -0.52 |
| Moving Average 50 Days | 4.17 |
| Moving Average 200 Days | 3.39 |
| Change | 0.01 |
If you invested $1000 in Alpha Tau Medical Ltd. (DRTS) since IPO date, it would be worth $501 as of December 26, 2025 at a share price of $5.06. Whereas If you bought $1000 worth of Alpha Tau Medical Ltd. (DRTS) shares 3 years ago, it would be worth $1,576.36 as of December 26, 2025 at a share price of $5.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
GlobeNewswire Inc.
Dec 18, 2025 2:00 PM GMT
- The overview presentation will review some of the Company’s recent achievements as well as the outlook for upcoming data milestones -JERUSALEM, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
GlobeNewswire Inc.
Dec 09, 2025 2:00 PM GMT
- First patient in the world treated with Alpha DaRT® in the brain – - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
GlobeNewswire Inc.
Dec 04, 2025 2:00 PM GMT
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026JERUSALEM, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS,